Real-world Evidence of Multiple Myeloma Treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland

<b>Background:</b> The rapid development of multiple myeloma (MM) management underscores the value of real-world data. In our study we examined 509 adult MM patients treated with immunochemotherapy (ICT) with/without stem cell transplantation (SCT) from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland. <b>Materials & methods:</b> Our study was based on computational analyses of data integrated into the hospital data lake. <b>Results:</b> After 2017, treatment pattern diversity increased with improved access to novel treatments. 5-year survivals were 74.4% (95% CI: 65.5-84.5) in SCT-eligible and 44.0% (95% CI: 37.6-51.4) in non-SCT subgroups. In the SCT-eligible subgroup, high first-year hospitalization costs were followed by stable resource requirements. <b>Conclusion:</b> Hospital data lakes can be adapted to carry out complex analysis of large MM cohorts.